Anglonordic is the only life science conference in the UK that is exclusively for European investors and R&D companies from the Nordics and the UK to connect with each other. With an established format of panel discussions, parallel technology and biotech investment rooms, plus 1:1 meetings, this 1-day London conference provides exceptional value. Investors with funds attend free-of-charge.
MEET decision makers at leading and upcoming drug discovery and technology companies from the UK and Nordic regions, along with investment firms from throughout Europe
LEARN from major investment firms about the current status of European investment in life science technologies
GAIN insights from experienced life science operators within the Anglo-Nordic space
The Anglonordic Life Science Conference has a “by-invitation-only” policy. The organisers welcome a limited number of service suppliers as sponsors or exhibitors.
The main conference room has a biotech investment focus; the technology room features devices, diagnostics, delivery and development tools. One-to-one meetings take place throughout the day. The Exhibition and quiet area double up for lunch service and refreshments are available all day.
One-to-one partnering meetings are pre-booked using the globally-renowned Meeting Mojo booking platform. Registered delegates can log in (Spring 2019) to browse profiles, set their own availability, request meetings, and promote their company to best advantage.
Networking begins on the evening before the conference with an exclusive Reception in Central London, free of charge to all registered delegates.
Applications for presentation slots are being accepted by registering on this site. DO NOT register here for delegate, sponsor, or exhibitor passes - instead follow the link in your invitation or request an invitation here.
Attendees at the 2018 event included companies from: Denmark, Finland, Germany, Luxembourg, Netherlands, Norway, Spain, Sweden, Switzerland, United Kingdom, and USA.
Organisations registered to attend in 2018 included:
Investors: 4BIO Capital, Abingworth, Advent Life Sciences, Albion Capital, Albion Technology & General VCT, Arix Bioscience, Axilium Holding AB, BioSeed Capital, Bleinheim Al Health, Bridge Valley Ventures, Capital Cell, Catapult Ventures, Curam Capital Management, Deepbridge Capital, Draper Esprit, Epidarex Capital, European Investment Bank, faceALS Foundation, Hadean Ventures, IAG, Ignite Capital Partners, Industrifonden, INKEF Capital, Innovator Capital, Investor Corporate AS, IP Group, IPF Partners, J&J Venture Investments, Limerston Capital, Longwall Ventures, M Ventures, Malin Coproration, Marten & Co, Medicxi, Momentum Biotech, MRL Ventures Fund, MVM Partners, National Institute for Health Research (NIHR), NCL Technology Ventures, NeoMed, NetScientific, New Science Global Healthcare Fund, Newable Private Investing, NewStock Capital, Norgine Ventures, Novo Holdings, o2h ventures, Oakstone Partners, RebelBio, Riverstone, Seventure Partners, Sofinnova, SR One, Sunstone Life Science Ventures, Trilantic Europe, Trinity Delta, UCB Ventures, Vita, Wellington Partners, W Global Capital, Wren Capital, Xontogeny.
Delegates: AdaptVac, Addbutment, Adenium Biotech ApS, Advanced Marker Discovery, Affibody, Albumedix, AM Oncology, APIM Therapeutics, Avilex Pharma, BioPartner UK, Biotech and Money, British Embassy Copenhagen, CatSci, Cederberg GmbH, Cell and Gene Therapy Catapult, CLS AB, Copenhagen Corporate Finance, Destina Genomica, Diamond Pharma, Department for International Trade, DNA Script, Domainex, EP Vantage, ESP Technology, Eurofins Amatsigroup, Eurofins Amatsigroup, Ezenze AB, Ferghana Partners, Financial Times, Forendo Pharma, f-star, Gedea Biotech, Immunitrack, Immunscape AB, Imperial College London Dept Bioengineering, Informa, ionctura, Jupiter Diagnostics, KaNDy Therapeutics, Karus Therapeutics, LactApp Women Health, Lavivo, Liberum, Lipopharma Therapeutics, LucyJRobertshaw, Lytics AI, Macrophage Pharma, MagCath Aps, Mallinckrodt Pharmaceuticals, Masters Speciality Pharma, MedCity, Medherant, MediCase, MediCheck, Medicon Valley Alliance, MediWales, Mergermarket, Meeting Mojo, Methodicare, Mind the Byte, Mission Therapeutics, MonTa Biosciences, Nature Research (Publishing), Neurofix S.L., One Nucleus, Optimum Strategic Communications, Oryzon Genomics SA, Paras Biopharmaceuticals Finland Oy, Pharmaceutical Executive Magazine, pharmaphorum, Plaquetec, Pluvia, Pneumagen, Precision Oncology, Prophylix AS, Protein Alternatives (ProAlt), Public Health England, RemAb, ReproUnion/EAU, Riverstone, Sahlgrenska Science Park, Sartar Therapeutics, Scrip Pharma Intelligence, Sidekick Health, Spanish Bioindustry Association - ASEBIO, Spherium Biomed, Stifel, SurgaColl Technologies, Swecare, Sygnature Discovery, Synaffix BV, TechGen International, The Bank of New York Mellon, The Cure Parkinson's Trust, The Fulford Group, The NHSA, TherapeutAix UG, Thrombolytic Science, Tummy Lab AB, Turku Science Park, VCN Biosciences, Yaqrit, Zilico.
Pharma Abbvie, ALMIRALL, Astellas, BTG International, Eli Lilly, Ferring Pharmaceuticals, Johnson & Johnson Innovation, MedImmune, Merck KGaA, Pfizer, Sandoz International GmbH, Simcere Pharmaceutical Group, Teijin Pharma.